Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460265
Status:
COMPLETED
Last Update Posted:
2014-03-07
First Post:
2007-04-12
Brief Title:
Study of Panitumumab Efficacy in Patients With Recurrent andor Metastatic Head and Neck Cancer
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic andor Recurrent Squamous Cell Carcinoma of the Head and Neck SCCHN
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SPECTRUM
Brief Summary:
The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic andor recurrent squamous cell carcinoma of the head and neck
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None